EXL Share Price Performance
€2.38
-0.67 (-21.97%)
53.3% undervalued intrinsic discount
€5.10
Fair Value
Price €2.38
AnalystConsensusTarget €5.10
Fair Value€5.10
Share Pricen/a
Analysis Article • May 19
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
EXL Community Narratives
AN
Fair Value
·Fair Value €5.1 53.3% undervalued intrinsic discount
Hybrid Analytics Will Serve Finance And Healthcare Markets
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Hybrid Analytics Will Serve Finance And Healthcare Markets
Key Takeaways Strategic focus on regulated industries and hybrid solutions positions Exasol for niche market growth while leveraging data repatriation trends for increased revenue. Cost-efficient strategies and new AI capabilities support profitability and competitive advantage, enhancing scalability and ARR growth in target regions.Read more
AN
€5.1
53.3% undervalued intrinsic discount
Fair Value
Revenue
8.48% p.a.
Profit Margin
11.9%
Future PE
25.13x
Price in 2028
€0
Trending Discussion
Recently Updated Narratives
AN
Hybrid Analytics Will Serve Finance And Healthcare Markets
Fair Value: €5.1 53.3% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Exasol AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 19, 2026
- 0.11
- 29.23%
- 7.16%
- 0%
About EXL
- Founded
- 2000
- Employees
- 160
- CEO
- WebsiteView website
Exasol AG, a technology company, engages in the provision of an analytics engine to access and analyze a company’s data in Germany, Austria, Switzerland, Europe, the United Kingdom, and the United States. It offers Exasol analytics engine, an in-memory engine designed for near real-time analytics, data warehousing, and AI/ML workloads. It serves e-commerce and retail, banking and insurance, hedge funds, and healthcare and pharma industries. The company was founded in 2000 and is headquartered in Nuremberg, Germany.
